For Asian MDS patients, Gu et al. proposed the mutation combined with the revised IPSS-R, namely MIPSS-R, taking into account the number of mutations and presence of SF3B1 mutations. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.